Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Fred Saad

Showing results (501-510 of 993) with videos related to

Pageof 100
Sort By:
American Journal of Clinical Oncology|May 30, 2020
The Effect of Systemic Chemotherapy on Survival in Patients With Localized, Regional, or Metastatic Adenocarcinoma of the Urinary BladderStefano Luzzago, Carlotta Palumbo, Giuseppe Rosiello, et al.
European Urology Oncology|May 22, 2021
Phase 3 Randomized Controlled Trial of Androgen Deprivation Therapy with or Without Docetaxel in High-risk Biochemically Recurrent Prostate Cancer After Surgery (TAX3503)Michael J Morris, Jose Mauricio Mota, Kristine Lacuna, et al.
Clinical Genitourinary Cancer|October 8, 2021
Radical Cystectomy vs. Radiotherapy in Urothelial Bladder Cancer in Elderly and Very Elderly PatientsBenedikt Horlemann, Christoph Würnschimmel, Benedikt Hoeh, et al.
Prostate Cancer and Prostatic Diseases|September 14, 2021
Impact of enzalutamide on patient-reported fatigue in patients with prostate cancer: data from the pivotal clinical trialsBertrand F Tombal, Stephen J Freedland, Andrew J Armstrong, et al.
European Urology Oncology|August 15, 2019
Development and Validation of a Lookup Table for the Prediction of Metastatic Prostate Cancer According to Prostatic-specific Antigen Value, Clinical Tumor Stage, and Gleason Grade GroupsFelix Preisser, Marco Bandini, Sebastiano Nazzani, et al.
International Journal of Radiation Oncology, Biology, Physics|February 2, 2010
The rate of secondary malignancies after radical prostatectomy versus external beam radiation therapy for localized prostate cancer: a population-based study on 17,845 patientsNaeem Bhojani, Umberto Capitanio, Nazareno Suardi, et al.
European Urology Focus|May 27, 2018
Validation of the Social Security Administration Life Tables (2004-2014) in Localized Prostate Cancer Patients within the Surveillance, Epidemiology, and End Results databaseFelix Preisser, Marco Bandini, Elio Mazzone, et al.
The Lancet. Oncology|June 9, 2018
Olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: a randomised, double-blind, placebo-controlled, phase 2 trialNoel Clarke, Pawel Wiechno, Boris Alekseev, et al.
Prostate Cancer and Prostatic Diseases|January 18, 2018
Tumor characteristics, treatments, and oncological outcomes of prostate cancer in men aged ≤50 years: a population-based studyRaisa S Pompe, Ariane Smith, Marco Bandini, et al.
Urologia Internationalis|August 4, 2016
Differences in Patient Characteristics among Men Choosing Open or Robot-Assisted Radical Prostatectomy in Contemporary Practice - Analysis of Surveillance, Epidemiology, and End Results DatabaseJonas Schiffmann, Alessandro Larcher, Maxine Sun, et al.
Pageof 100

Showing results (501-510 of 993) with videos related to

Sort By:
Pageof 100
American Journal of Clinical Oncology|May 30, 2020
The Effect of Systemic Chemotherapy on Survival in Patients With Localized, Regional, or Metastatic Adenocarcinoma of the Urinary BladderStefano Luzzago, Carlotta Palumbo, Giuseppe Rosiello, et al.
European Urology Oncology|May 22, 2021
Phase 3 Randomized Controlled Trial of Androgen Deprivation Therapy with or Without Docetaxel in High-risk Biochemically Recurrent Prostate Cancer After Surgery (TAX3503)Michael J Morris, Jose Mauricio Mota, Kristine Lacuna, et al.
Clinical Genitourinary Cancer|October 8, 2021
Radical Cystectomy vs. Radiotherapy in Urothelial Bladder Cancer in Elderly and Very Elderly PatientsBenedikt Horlemann, Christoph Würnschimmel, Benedikt Hoeh, et al.
Prostate Cancer and Prostatic Diseases|September 14, 2021
Impact of enzalutamide on patient-reported fatigue in patients with prostate cancer: data from the pivotal clinical trialsBertrand F Tombal, Stephen J Freedland, Andrew J Armstrong, et al.
European Urology Oncology|August 15, 2019
Development and Validation of a Lookup Table for the Prediction of Metastatic Prostate Cancer According to Prostatic-specific Antigen Value, Clinical Tumor Stage, and Gleason Grade GroupsFelix Preisser, Marco Bandini, Sebastiano Nazzani, et al.
International Journal of Radiation Oncology, Biology, Physics|February 2, 2010
The rate of secondary malignancies after radical prostatectomy versus external beam radiation therapy for localized prostate cancer: a population-based study on 17,845 patientsNaeem Bhojani, Umberto Capitanio, Nazareno Suardi, et al.
European Urology Focus|May 27, 2018
Validation of the Social Security Administration Life Tables (2004-2014) in Localized Prostate Cancer Patients within the Surveillance, Epidemiology, and End Results databaseFelix Preisser, Marco Bandini, Elio Mazzone, et al.
The Lancet. Oncology|June 9, 2018
Olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: a randomised, double-blind, placebo-controlled, phase 2 trialNoel Clarke, Pawel Wiechno, Boris Alekseev, et al.
Prostate Cancer and Prostatic Diseases|January 18, 2018
Tumor characteristics, treatments, and oncological outcomes of prostate cancer in men aged ≤50 years: a population-based studyRaisa S Pompe, Ariane Smith, Marco Bandini, et al.
Urologia Internationalis|August 4, 2016
Differences in Patient Characteristics among Men Choosing Open or Robot-Assisted Radical Prostatectomy in Contemporary Practice - Analysis of Surveillance, Epidemiology, and End Results DatabaseJonas Schiffmann, Alessandro Larcher, Maxine Sun, et al.
Pageof 100